{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HRD+Cancer&page=2",
    "query": {
      "condition": "HRD Cancer",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HRD+Cancer&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T19:32:56.612Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01982448",
      "title": "Cisplatin vs Paclitaxel for Triple Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 147,
      "start_date": "2014-04",
      "completion_date": "2020-08",
      "has_results": true,
      "last_update_posted_date": "2025-09-30",
      "last_synced_at": "2026-06-26T19:32:56.612Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • Indianapolis, Indiana • Baltimore, Maryland + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01982448"
    },
    {
      "nct_id": "NCT03355066",
      "title": "A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "SM08502",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biosplice Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 82,
      "start_date": "2017-11-06",
      "completion_date": "2022-11-14",
      "has_results": false,
      "last_update_posted_date": "2024-08-09",
      "last_synced_at": "2026-06-26T19:32:56.612Z",
      "location_count": 19,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 14 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03355066"
    },
    {
      "nct_id": "NCT06458712",
      "title": "Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Metastases)"
      ],
      "interventions": [
        {
          "name": "DSB2455",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke Street Bio Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2024-11-21",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-06-26T19:32:56.612Z",
      "location_count": 3,
      "location_summary": "New Haven, Connecticut • New York, New York • Houston, Texas",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06458712"
    },
    {
      "nct_id": "NCT04983745",
      "title": "Niraparib and Dostarlimab in HRD Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Homologous Recombination Deficient Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Combination drug",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "West Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "Up to 100 Years"
      },
      "enrollment_count": 30,
      "start_date": "2021-11-29",
      "completion_date": "2025-08",
      "has_results": false,
      "last_update_posted_date": "2023-12-21",
      "last_synced_at": "2026-06-26T19:32:56.612Z",
      "location_count": 1,
      "location_summary": "Germantown, Tennessee",
      "locations": [
        {
          "city": "Germantown",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04983745"
    },
    {
      "nct_id": "NCT03397394",
      "title": "Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer",
        "Urothelial Carcinoma",
        "Metastatic Urothelial Carcinoma",
        "Renal Pelvis Carcinoma",
        "Ureter Carcinoma",
        "Urinary Bladder Carcinoma",
        "Urethra Carcinoma",
        "Muscle Invasive Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Rucaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "pharmaand GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 97,
      "start_date": "2018-06-01",
      "completion_date": "2020-01-15",
      "has_results": true,
      "last_update_posted_date": "2023-06-09",
      "last_synced_at": "2026-06-26T19:32:56.612Z",
      "location_count": 41,
      "location_summary": "Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 35 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03397394"
    },
    {
      "nct_id": "NCT07318558",
      "title": "A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ovarian Neoplasms",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Sacituzumab tirumotecan",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Rescue Medications",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 900,
      "start_date": "2026-02-16",
      "completion_date": "2033-02-25",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-06-26T19:32:56.612Z",
      "location_count": 10,
      "location_summary": "Miami Beach, Florida • Orlando, Florida • Atlanta, Georgia + 6 more",
      "locations": [
        {
          "city": "Miami Beach",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        },
        {
          "city": "Covington",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07318558"
    },
    {
      "nct_id": "NCT02401347",
      "title": "Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Breast Cancer",
        "HER2/Neu Negative",
        "Triple-Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Talazoparib Tosylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Melinda Telli",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2015-08",
      "completion_date": "2022-12",
      "has_results": true,
      "last_update_posted_date": "2023-02-21",
      "last_synced_at": "2026-06-26T19:32:56.612Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02401347"
    },
    {
      "nct_id": "NCT06856499",
      "title": "Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Endometrioid Ovarian Cancer",
        "Primary Peritoneal Cancer",
        "Fallopian Tube Cancer"
      ],
      "interventions": [
        {
          "name": "Cirtuvivint",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2025-12-08",
      "completion_date": "2029-07",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-06-26T19:32:56.612Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06856499"
    },
    {
      "nct_id": "NCT05659381",
      "title": "Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Stage III Ovarian Cancer",
        "Stage IV Ovarian Cancer",
        "Stage III Primary Peritoneal Cancer",
        "Stage IV Primary Peritoneal Cancer",
        "Stage III Fallopian Tube Cancer",
        "Stage IV Fallopian Tube Cancer"
      ],
      "interventions": [
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "No treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "GOG Foundation",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 220,
      "start_date": "2024-03-08",
      "completion_date": "2034-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-06-26T19:32:56.612Z",
      "location_count": 59,
      "location_summary": "Duarte, California • La Jolla, California • Newport Beach, California + 43 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05659381"
    },
    {
      "nct_id": "NCT04515836",
      "title": "Olaparib in Patients With HRD Malignant Mesothelioma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mesothelioma",
        "Homologous Recombination Deficiency"
      ],
      "interventions": [
        {
          "name": "Olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2021-02-19",
      "completion_date": "2028-04-15",
      "has_results": false,
      "last_update_posted_date": "2025-05-06",
      "last_synced_at": "2026-06-26T19:32:56.612Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04515836"
    }
  ]
}